Details of a Researcher - Uchida, Hiroyuki

Papers - Uchida, Hiroyuki

Division display 421 - 440 of about 567 ／ All the affair displays >>

Role of sonic hedgehog signaling in migration of cell lines established from CD133-positive malignant glioma cells.

Uchida H, Arita K, Yunoue S, Yonezawa H, Shinsato Y, Kawano H, Hirano H, Hanaya R, Tokimura H

Journal of neuro-oncology 104 ( 3 ) 697 - 704 2011.09

ISSN 0167-594X

Access to Document (DOI)

Species-specific functional evolution of neuroglobin.

Wakasugi K, Takahashi N, Uchida H, Watanabe S

Marine genomics 4 ( 3 ) 137 - 42 2011.09

ISSN 1874-7787

Access to Document (DOI)

The evolution of antipsychotic switch and polypharmacy in natural practice - A longitudinal perspective

Tsutsumi Chisa, Uchida Hiroyuki, Suzuki Takefumi, Watanabe Koichiro, Takeuchi Hiroyoshi, Nakajima Shinichiro, Kimura Yoshie, Tsutsumi Yuichiro, Ishii Koichi, Imasaka Yasushi, Kapur Shitij

Schizophrenia Research (Schizophrenia Research) 130 ( 1-3 ) 40 - 46 2011.08

ISSN 0920-9964

Objective: Most patients with schizophrenia first start with a single antipsychotic, and yet most finally end up 'switching' or using 'polypharmacy'. The objective of this study was to examine the evolution of antipsychotic switch and polypharmacy in the real-world from a longitudinal perspective. Methods: A systematic review of longitudinal antipsychotic prescriptions in 300 patients with schizophrenia (ICD-10) for up to 2. years after their first visit to one of the 4 participating psychiatric clinics in Tokyo, Japan between January, 2007 and June, 2008, was conducted. Reasons for prescription change were also examined. The evolution of switching and polypharmacy was studied, and prescribed doses were compared to suggested dose ranges by the Texas Medication Algorithm Project (TMAP). Results: 208 patients started their antipsychotic treatment with monotherapy. 34.1% of the patients gave up monotherapy with an initial antipsychotic to move to antipsychotic switch (27.4%) and/or polypharmacy (17.8%) within 2. years. The main reason for antipsychotic switch was 'ineffectiveness'; interestingly, this happened despite the fact that the monotherapy dose was below the recommended range in 47.4% of the antipsychotic switch. In a subgroup of 100 patients who started as antipsychotic-free, 2-year prevalence rates of switching and antipsychotic polypharmacy were 27.0% and 18.0%, respectively, and polypharmacy was resorted to after a median of 1 antipsychotic had been tried for 84. days (median). Conclusions: These findings raise a concern that physicians may perform an antipsychotic switch without exploring the entire dose range and resort to antipsychotic polypharmacy without trying an adequate number of antipsychotics.

Access to Document (DOI)

Dopamine D₂ receptor occupancy and clinical effects

Uchida Hiroyuki, Takeuchi Hiroyoshi, Graff-Guerrero Ariel, Suzuki Takefumi, Watanabe Koichiro, Mamo David C.

Journal of Clinical Psychopharmacology 31 ( 4 ) 497 - 502 2011.08

ISSN 0271-0749

Positron emission tomography (PET) studies proposed a therapeutic window of D₂ receptor occupancy (65%-80%) of antipsychotics for the treatment of schizophrenia in young adults. However, this conclusion has been drawn from clinical PET studies using small sample sizes (<20). Prospective PET studies that measured D₂ occupancy levels and assessed extrapyramidal side effects (EPS) and/or treatment response induced by antipsychotics (excluding partial agonists) were identified, using MEDLINE and EMBASE (last search: March 2010). Individual subjects were divided into 2 groups based on EPS status (ie, presence or lack of newly emergent EPS) and treatment response (ie, a â‰¥ 25% or â‰¥ 50% reduction in the Positive and Negative Syndrome Scale or Brief Psychiatric Rating Scale). To evaluate the performance of this binary classification, sensitivity, specificity, and accuracy of consecutive cutoff points in the D₂ occupancy were calculated: Accuracy = (True Positive + True Negative)/Total N. Twelve studies, including a total of 82 subjects, were included in our analyses. The cutoff points associated with 0.5 or greater in both sensitivity and specificity with the greatest accuracy were 77% to 78% for EPS, 60% for a 25% or greater symptom reduction, and 72% for a 50% or greater symptom reduction. These findings support the presence of a therapeutic window of 60% to 78% D₂ occupancy of antipsychotics in young adults with schizophrenia and may suggest the presence of a continuum of effectiveness with increasing occupancy within this therapeutic window.

Access to Document (DOI)

How long to wait before reducing antipsychotic dosage in stabilized patients with schizophrenia? A retrospective chart review

Takeuchi Hiroyoshi, Suzuki Takefumi, Uchida Hiroyuki, Kikuchi Toshiaki, Nakajima Shinichiro, Manki Hiroshi, Watanabe Koichiro, Kashima Haruo

Journal of Psychiatric Research (Journal of Psychiatric Research) 45 ( 8 ) 1083 - 1088 2011.08

ISSN 0022-3956

Objective: Antipsychotic dose reduction is generally recommended to occur after six months of clinical stabilization despite inadequate evidence. This timing issue was addressed in this study. Methods: This is an observational, retrospective and medical chart-based study. Inclusion criteria were (1) diagnosis of schizophrenia (DSM-IV), (2) being acutely psychotic at their first outpatient visit from May, 2002 to April, 2003, (3) having responded to antipsychotics and achieved clinical stabilization of acute symptoms, indexed as a fixation of regimen for four or more weeks, and (4) having one or more years of follow-up. Patients who had their antipsychotic doses reduced were then identified, and they were divided into two groups based on the waiting period before dose reduction: <24 weeks (Early Group) and ≥24 weeks (Standard Group). The rate of dose escalation for ≥20% during follow-up period was investigated as a proxy of clinical worsening. Results: After excluding stable patients at baseline, 211 patients met inclusion criteria. The mean ± SD waiting period before reducing antipsychotics was 122 ± 102 days. The rates of patients needing dose escalation were not significantly different between patients whose dose was reduced (N = 83) and those who was not (N = 128) (57.8% vs. 59.4%), and between Early Group (N = 59) and Standard Group (N = 24) (61.0% vs. 50.0%) although the reduction rate in antipsychotic dosage was significantly greater in Early Group (58.7% vs. 43.3%, p < 0.05). Conclusion: These findings may indicate that timeline until antipsychotic reduction in stable patients with schizophrenia could be earlier than recommended, although caution is needed in interpreting our retrospective results.

Access to Document (DOI)

Plasma substance P level in patients with schizophrenia

Ishida Takuto, Uchida Hiroyuki, Suzuki Takefumi, Nakajima Shinichiro, Watanabe Koichiro, Kashima Haruo

Psychiatry and Clinical Neurosciences 65 ( 5 ) 526 - 528 2011.08

ISSN 1323-1316

Aspiration pneumonia is a serious health concern in older patients with schizophrenia. In this study, we examined clinical and demographic variables that could impact the plasma substance P level, which is a useful predictive biomarker of aspiration. Thirty-four patients were included (mean age ± SD: 70.9 ± 10.8 years). A greater number of cigarettes/day and a higher antipsychotic dosage were found to be associated with a lower plasma substance P level, while age showed a trend-level effect. This finding suggests the need for intensive observation for prevention of aspiration pneumonia in heavy smokers who are receiving a higher antipsychotic dose in this senior population.

Access to Document (DOI)

Dopamine D<inf>2</inf> receptor occupancy and clinical effects: A systematic review and pooled analysis

Uchida H., Takeuchi H., Graff-Guerrero A., Suzuki T., Watanabe K., Mamo D.

Journal of Clinical Psychopharmacology (Journal of Clinical Psychopharmacology) 31 ( 4 ) 497 - 502 2011.08

ISSN 02710749

Positron emission tomography (PET) studies proposed a therapeutic window of D2 receptor occupancy (65%-80%) of antipsychotics for the treatment of schizophrenia in young adults. However, this conclusion has been drawn from clinical PET studies using small sample sizes (<20). Prospective PET studies that measured D2 occupancy levels and assessed extrapyramidal side effects (EPS) and/or treatment response induced by antipsychotics (excluding partial agonists) were identified, using MEDLINE and EMBASE (last search: March 2010). Individual subjects were divided into 2 groups based on EPS status (ie, presence or lack of newly emergent EPS) and treatment response (ie, a â‰¥ 25% or â‰¥ 50% reduction in the Positive and Negative Syndrome Scale or Brief Psychiatric Rating Scale). To evaluate the performance of this binary classification, sensitivity, specificity, and accuracy of consecutive cutoff points in the D2 occupancy were calculated: Accuracy = (True Positive + True Negative)/Total N. Twelve studies, including a total of 82 subjects, were included in our analyses. The cutoff points associated with 0.5 or greater in both sensitivity and specificity with the greatest accuracy were 77% to 78% for EPS, 60% for a 25% or greater symptom reduction, and 72% for a 50% or greater symptom reduction. These findings support the presence of a therapeutic window of 60% to 78% D2 occupancy of antipsychotics in young adults with schizophrenia and may suggest the presence of a continuum of effectiveness with increasing occupancy within this therapeutic window. © 2011 Lippincott Williams & Wilkins.

Access to Document (DOI)

Plasma substance P level in patients with schizophrenia: A cross-sectional study

Ishida T., Uchida H., Suzuki T., Nakajima S., Watanabe K., Kashima H.

Psychiatry and Clinical Neurosciences (Psychiatry and Clinical Neurosciences) 65 ( 5 ) 526 - 528 2011.08

ISSN 13231316

Aspiration pneumonia is a serious health concern in older patients with schizophrenia. In this study, we examined clinical and demographic variables that could impact the plasma substance P level, which is a useful predictive biomarker of aspiration. Thirty-four patients were included (mean age ± SD: 70.9 ± 10.8 years). A greater number of cigarettes/day and a higher antipsychotic dosage were found to be associated with a lower plasma substance P level, while age showed a trend-level effect. This finding suggests the need for intensive observation for prevention of aspiration pneumonia in heavy smokers who are receiving a higher antipsychotic dose in this senior population. © 2011 Japanese Society of Psychiatry and Neurology.

Access to Document (DOI)

Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia

Uchida Hiroyuki, Suzuki Takefumi, Takeuchi Hiroyoshi, Arenovich Tamara, Mamo David C.

Schizophrenia Bulletin 37 ( 4 ) 788 - 799 2011.07

ISSN 0586-7614

Background: It remains unknown as to whether the antipsychotic dose needed for the acute-phase treatment of schizophrenia is also necessary for relapse prevention. Aim: To compare the efficacy between standard dose [(World Health Organization daily defined dose (DDD)] vs low dose (≥50% to <1 DDD) or very low dose (<50% DDD) for relapse prevention in schizophrenia. Data source: Double-blind, randomized, controlled trials with a follow-up duration of ≥24 weeks, including ≥2 dosage groups of the same antipsychotic drug for relapse prevention in schizophrenia, were searched using MEDLINE, the Cochrane Central Register of Controlled Trials, and EMBASE (last search: August 2009). Data extraction: Data on overall treatment failure, hospitalization, relapse, and dropouts due to side effects were extracted and combined in a meta-analysis. Data synthesis: Thirteen studies with 1395 subjects were included in this meta-analysis. Compared with the standard-dose treatment, the low-dose therapy did not show any statistically significant difference in overall treatment failure or hospitalization, while the standard dose showed a trend-level (P =. 05) superiority in risk of relapse. The very low-dose group was inferior to the standard-dose group in all efficacy parameters. No significant difference was found in the rate of dropouts due to side effects between either standard dose vs low dose or very low dose. Conclusions: Although antipsychotic treatment with ≥50% to <1 DDD may be as effective as standard-dose therapy, there are insufficient clinical trial data to draw firm conclusions on standard- vs low-dose maintenance antipsychotic therapy for schizophrenia.

Access to Document (DOI)

Gender differences in age, period, and birth-cohort effects on the suicide mortality rate in Japan, 1985-2006.

Odagiri Y, Uchida H, Nakano M

Asia-Pacific journal of public health 23 ( 4 ) 581 - 7 2011.07

ISSN 1010-5395

Access to Document (DOI)

Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: Meta-analysis

Uchida H., Suzuki T., Takeuchi H., Arenovich T., Mamo D.C.

Schizophrenia Bulletin (Schizophrenia Bulletin) 37 ( 4 ) 788 - 799 2011.07

ISSN 05867614

Background: It remains unknown as to whether the antipsychotic dose needed for the acute-phase treatment of schizophrenia is also necessary for relapse prevention. Aim: To compare the efficacy between standard dose [(World Health Organization daily defined dose (DDD)] vs low dose (≥50% to <1 DDD) or very low dose (<50% DDD) for relapse prevention in schizophrenia. Data source: Double-blind, randomized, controlled trials with a follow-up duration of ≥24 weeks, including ≥2 dosage groups of the same antipsychotic drug for relapse prevention in schizophrenia, were searched using MEDLINE, the Cochrane Central Register of Controlled Trials, and EMBASE (last search: August 2009). Data extraction: Data on overall treatment failure, hospitalization, relapse, and dropouts due to side effects were extracted and combined in a meta-analysis. Data synthesis: Thirteen studies with 1395 subjects were included in this meta-analysis. Compared with the standard-dose treatment, the low-dose therapy did not show any statistically significant difference in overall treatment failure or hospitalization, while the standard dose showed a trend-level (P =. 05) superiority in risk of relapse. The very low-dose group was inferior to the standard-dose group in all efficacy parameters. No significant difference was found in the rate of dropouts due to side effects between either standard dose vs low dose or very low dose. Conclusions: Although antipsychotic treatment with ≥50% to <1 DDD may be as effective as standard-dose therapy, there are insufficient clinical trial data to draw firm conclusions on standard- vs low-dose maintenance antipsychotic therapy for schizophrenia. © The Author 2011. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved.

Access to Document (DOI)

Sulfonated poly(arylene ether sulfone ketone) multiblock copolymers with highly sulfonated blocks. Long-term fuel cell operation and post-test analyses.

Bae B, Miyatake K, Uchida M, Uchida H, Sakiyama Y, Okanishi T, Watanabe M

ACS applied materials & interfaces 3 ( 7 ) 2786 - 93 2011.07

ISSN 1944-8244

Access to Document (DOI)

Predicting dopamine D₂ receptor occupancy from plasma levels of antipsychotic drugs

Uchida Hiroyuki, Takeuchi Hiroyoshi, Graff-Guerrero Ariel, Suzuki Takefumi, Watanabe Koichiro, Mamo David C.

Journal of Clinical Psychopharmacology 31 ( 3 ) 318 - 325 2011.06

ISSN 0271-0749

Measuring dopamine D2 receptor occupancy levels using positron emission tomography (PET) is still widely unavailable. The objective of this study was to evaluate the accuracy of predicting D2 occupancy from the antipsychotic plasma level in patients with schizophrenia. Positron emission tomographic studies that measured plasma levels of antipsychotics and their corresponding D2 occupancy levels were identified, using MEDLINE and EMBASE (last search: March 2010). Antipsychotics that were investigated in a total of 20 subjects or more were included. All data points for each antipsychotic were fit to a one-site binding model to estimate the total plasma concentration of each antipsychotic associated with a 50% occupancy (ED50) of brain D2 receptors. The mean prediction error and the root mean squared prediction error were used to measure the predictive performance of individual D2 receptor occupancies from plasma drug levels derived from a one-site occupancy model using an ED50 value calculated for each data point. A total of 34 treatment arms from 23 studies involving 281 subjects were included. The mean (95% confidence interval) prediction errors and root squared prediction errors were as low as 0.0 (-1.8 to 1.8) and 8.9 (7.6-10.2) for risperidone (n = 98); 0.0 (-3.5 to 3.5) and 15.1 (12.9-17.3) for clozapine (n = 75); -0.1 (-1.2 to 1.2), 0.0 (-1.9 to 1.9), and 4.6 (3.5-5.8) for olanzapine (n = 42); 0.1 (-3.4 to 3.5) and 9.9 (7.3-12.5) for haloperidol (n = 35); and -0.1 (-3.3 to 3.1) and 12.3 (8.8-15.7) for ziprasidone (n = 31), respectively. These findings suggest that D2 occupancy of antipsychotics could be estimated with a high degree of accuracy using widely available plasma levels.

Access to Document (DOI)

A tipping point in drug dosing in late-life schizophrenia

Tsuboi Takashi, Suzuki Takefumi, Uchida Hiroyuki

Current Psychiatry Reports (Current Psychiatry Reports) 13 ( 3 ) 225 - 233 2011.06

ISSN 1523-3812

Minimally effective doses of antipsychotics are likely influenced by several clinical and demographic characteristics of patients, with age being one of the most important elements. In light of age-related physiologic changes as well as interindividual differences in pharmacokinetic and pharmacodynamic systems, individualized dosing with regard to age will be critically important for safer drug treatment for older patients with schizophrenia. In the present review, we propose the following cautious psychopharmacologic interventions for this population: 1) simple regimen (avoid polypharmacy), 2) be aware of the presence of patients who are very sensitive to drugs, 3) gradual dose titration, and 4) timely and thorough assessments of therapeutic and side effects. The age-related antipsychotic sensitivity highlights the importance of finding the lowest possible effective dose of antipsychotic drugs as patients with schizophrenia age to maximize therapeutic effects and minimize side effects.

Access to Document (DOI)

Adsorption and oxidation of carbon monoxide on Pt/C, Pt3Co/C, and PtRu/C catalysts studied by in-situ attenuated total reflection Fourier-transform infrared.

Sato T, Kunimatsu K, Watanabe M, Uchida H

Journal of nanoscience and nanotechnology 11 ( 6 ) 5123 - 30 2011.06

ISSN 1533-4880

Access to Document (DOI)

Characterization of systemic and histologic injury after crush syndrome and intervals of reperfusion in a small animal model.

Murata I, Ooi K, Sasaki H, Kimura S, Ohtake K, Ueda H, Uchida H, Yasui N, Tsutsui Y, Yoshizawa N, Hirotsu I, Morimoto Y, Kobayashi J

The Journal of trauma 70 ( 6 ) 1453 - 63 2011.06

ISSN 0022-5282

Access to Document (DOI)

Predicting dopamine D<inf>2</inf> receptor occupancy from plasma levels of antipsychotic drugs: A systematic review and pooled analysis

Uchida H., Takeuchi H., Graff-Guerrero A., Suzuki T., Watanabe K., Mamo D.

Journal of Clinical Psychopharmacology (Journal of Clinical Psychopharmacology) 31 ( 3 ) 318 - 325 2011.06

ISSN 02710749

Measuring dopamine D2 receptor occupancy levels using positron emission tomography (PET) is still widely unavailable. The objective of this study was to evaluate the accuracy of predicting D2 occupancy from the antipsychotic plasma level in patients with schizophrenia. Positron emission tomographic studies that measured plasma levels of antipsychotics and their corresponding D2 occupancy levels were identified, using MEDLINE and EMBASE (last search: March 2010). Antipsychotics that were investigated in a total of 20 subjects or more were included. All data points for each antipsychotic were fit to a one-site binding model to estimate the total plasma concentration of each antipsychotic associated with a 50% occupancy (ED50) of brain D2 receptors. The mean prediction error and the root mean squared prediction error were used to measure the predictive performance of individual D2 receptor occupancies from plasma drug levels derived from a one-site occupancy model using an ED50 value calculated for each data point. A total of 34 treatment arms from 23 studies involving 281 subjects were included. The mean (95% confidence interval) prediction errors and root squared prediction errors were as low as 0.0 (-1.8 to 1.8) and 8.9 (7.6-10.2) for risperidone (n = 98); 0.0 (-3.5 to 3.5) and 15.1 (12.9-17.3) for clozapine (n = 75); -0.1 (-1.2 to 1.2), 0.0 (-1.9 to 1.9), and 4.6 (3.5-5.8) for olanzapine (n = 42); 0.1 (-3.4 to 3.5) and 9.9 (7.3-12.5) for haloperidol (n = 35); and -0.1 (-3.3 to 3.1) and 12.3 (8.8-15.7) for ziprasidone (n = 31), respectively. These findings suggest that D2 occupancy of antipsychotics could be estimated with a high degree of accuracy using widely available plasma levels. © 2011 Lippincott Williams & Wilkins.

Access to Document (DOI)

広汎性発達障害児の人物画研究　DAM項目による身体部位表現の分析

明翫光宜, 望月知世, 内田裕之, 辻井正次

小児の精神と神経 ((一社)日本小児精神神経学会) 51 ( 2 ) 157 - 168 2011.06

ISSN 0559-9040

本研究では、広汎性発達障害児の人物画の特徴を捉えるために、定型発達児との比較研究を行った。対象は広汎性発達障害群30名(男児)、定型発達群97名(男児)であった。DAM項目について両群を比較したところ、DAM-IQなどの総合指標だけの分析では広汎性発達障害の心理査定に限界があり、人物画に描かれている身体部位表現に注目することの重要性を示唆した。(著者抄録)

Electrochemical quartz crystal microbalance analysis of the oxygen reduction reaction on Pt-based electrodes. Part 1: Effect of adsorbed anions on the oxygen reduction activities of Pt in HF, HClO4, and H2SO4 solutions.

Omura J, Yano H, Watanabe M, Uchida H

Langmuir : the ACS journal of surfaces and colloids 27 ( 10 ) 6464 - 70 2011.05

ISSN 0743-7463

Access to Document (DOI)

[Age-, period-, and birth-cohort-specific effects on the male proportion in Japanese newborns and projections for male proportion for 20 periods (2008-2027)].

Uchida H, Watanabe M, Naiki M, Ito J, Ohtake K, Odagiri Y, Kobayashi J

Nihon eiseigaku zasshi. Japanese journal of hygiene 66 ( 3 ) 582 - 8 2011.05

ISSN 0021-5082

Access to Document (DOI)

　 Previous page - Next page 　